1. Halbrook CJ, Lyssiotis CA, di Magliano MP, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186(8):1729-54. doi.10.1016/j.cell.2023.02.014 PMid:37059070 PMCid:PMC10182830

2. Lee Y, Lee K. Pancreatic diseases: genetics and modeling using human pluripotent stem cells. International journal of stem cells. 2024;17(3):253-69. doi.10.15283/ijsc24036 PMid:38664226 PMCid:PMC11361847

3. Bosnian FT, de Bruine A. Endocrine cells in nonendocrine tumors of the gut and pancreas. In: Endocrine pathology of the gut and pancreas. CRC Press; 2024. p.319-38. doi.10.1201/9781003574668-12

4. Li X, Zhang Y, Yan Z, Jiang W, Rui S. Global, regional and National burden of pancreatic cancer and its attributable risk factors from 2019 to 2021, with projection to 2044. Front Oncol. 2025; 14:1521788. doi.10.3389/fonc.2024.1521788 PMid:39876895 PMCid:PMC11772166

5. Zhang Y, Wang P, Jia Z, Zheng Z, Wang J, Liang H. Global burden and risk factors of male cancers from 1990 to 2021, with forecasts to 2040. Scientific Reports. 2025;15(1):5123. doi.10.1038/s41598-025-88392-8 PMid:39934217 PMCid:PMC11814104

6. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. Ca. 2025;75(1):10. doi.10.3322/caac.21871 PMid:39817679 PMCid:PMC11745215

7. He S, Xia C, Li H, Cao M, Yang F, Yan X, et al. Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors. Sci China Life Sci. 2024; 67(1):122-31. doi.10.1007/s11427-023-2423-1 PMid:37755589

8. Reid JE, Pellegrini L, Drummond L, Varlakova Y, Shahper S, Baldwin DS, et al. Differential effects of sertraline and cognitive behavioural therapy on behavioural inhibition in patients with obsessive compulsive disorder. Int Clin Psychopharmacol. 2025; 40(3):148-55 doi.10.1097/YIC.0000000000000548 PMid:38568112

9. Blum CB, Dohrmann MJ, McCarthy L, McMenamin M, O'Callaghan LA. Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms. Pharmacol Res Perspect. 2025; 13(5):e70168. doi.10.1002/prp2.70168 PMid:40874450 PMCid:PMC12392137

10. Dominiak A, Chełstowska B, Nowicka G. Metabolic Adaptations in Cancer Progression: Optimization Strategies and Therapeutic Targets. Cancers. 2025;17(14):2341. doi.10.3390/cancers17142341 PMid:40723225 PMCid:PMC12293939

11. Zinnah KM, Seol JW, Park SY. Inhibition of autophagy flux by sertraline attenuates TRAIL resistance in lung cancer via death receptor 5 upregulation. International J molecular medicine. 2020; 46(2):795-805. doi.10.3892/ijmm.2020.4635 PMid:32626921 PMCid:PMC7307864

12. Duarte D, Vale N. Antidepressant drug sertraline against human cancer cells. Biomolecules. 2022;12(10):1513. doi.10.3390/biom12101513 PMid:36291722 PMCid:PMC9599050

13. Lin KL, Chi CC, Lu T, Tseng LL, Wang JL, Lu YC, Jan CR. Effect of sertraline on [Ca2+] i and viability of human MG63 osteosarcoma cells. Drug Chem Toxicol. 2013; 36(2):231-40. doi.10.3109/01480545.2012.710625 PMid:22931138

14. Fayyaz S, Irshad R, Siddiqui RA, Choudhary MI. Antidepressant sertraline hydrochloride inhibits the growth of HER2+ AU565 breast cancer cell line through induction of apoptosis and cell cycle arrest. Anticancer Agents Med Chem. 2024;24(14):1038-46. doi.10.2174/0118715206304918240509111700 PMid:38766835

15. Hebballi AP, Kumar MR P, Rajagopal K, Barua R, Alshehri MA, Rab SO, et al. Biological Roles and Pharmaceutical Applications of Metal-Complexed Coumarin Derivatives: A Comprehensive Review. Curr Organic Chem. 2025. doi.10.2174/0113852728333339250301184159

16. Oliva FM. The identification and characterization of serotonin receptors in cancer and their response to serotonin and selective serotonin reuptake inhibitors. Youngstown State University; 2024.

17. Máté L, Péter Á, Uray IP. G Protein Subtype Preference Dictates Paroxetine-Enhanced Serotonin Receptor Response in Non-Malignant Breast Epithelial Cells. Available at SSRN 5377139.

18. Singh K, Jain D, Sethi P, Gupta JK, Dubey A, Al Noman A, et al .Advances in viral vector-based delivery systems for gene therapy: a comprehensive review. 3 Biotech. 2025;15(7):196. doi.10.1007/s13205-025-04366-7 PMid:40454374

19. Yi W, Hu S, Qian X, Yan W, Li Y. Synthetic biology‐based engineering cells for drug delivery. In: Exploration. 2025;5(2):20240095. doi.10.1002/EXP.20240095 PMid:40395752 PMCid:PMC12087405

20. Zhang Y, Song Z, Zhang H, Lin H, Xu P, Li Z, et al. Advancing Antidepressive Agents: Drug Discovery and Polymer-Based Drug Delivery Systems for Improved Treatment Outcome. Biomedicines. 2025;13 (5): 1081. doi.10.3390/biomedicines13051081 PMid:40426909 PMCid:PMC12109423

21. Liao MZ, Sawant A, Corrigan B, Haertter S, Otsubo Y, Younis IR, et al. How Clinical Pharmacology Can Support Clinical Trial Diversity and Inclusion. Clin Transl Sci. 2025; 18(9):e70332. doi.10.1111/cts.70332 PMid:40857072 PMCid:PMC12379548

22. Malheiro V, Santos B, Figueiras A, Mascarenhas-Melo F. The potential of artificial intelligence in pharmaceutical innovation: From drug discovery to clinical trials. Pharmaceuticals. 2025;18(6):788. doi.10.3390/ph18060788 PMid:40573185 PMCid:PMC12195710

23. Camara H, Vicaut E, Caron B, Honap S, Baumann C, Peyrin-Biroulet L. Bayesian statistics: a narrative review on application in inflammatory bowel diseases. Inflamm Bowel Dis. 2025:izaf148. doi.10.1093/ibd/izaf148 PMid:40796196

24. Bardaweel SK, Hajjo R, Abusara OH, Sabbah D, Hattab D, Alabdullah AS, et al. An Overview of the Potential Use of Selective Serotonin Reuptake Inhibitors (SSRIs) in Cancer Treatment. Current Cancer Drug Targets. 2025. doi.10.2174/0115680096372733250611114329 PMid:40600564